38 patients (avg. age 49.0 ± 0.89) with chronic glomerulonephritis and arterial hypertension were examined. Diagnosis of chronic glomerulonephritis was verified by means of kidney biopsy. The patients were divided into 2 groups (19 patients in each group) comparable in terms of age, sex, duration of disease. Patients of the first group received a fixed combination of 2 drugs, the Perindopril in the dose of 5 mg and the Indapamide in the dose of 1.25 mg (Noliprel A Forte), patients of the second group – on free combination of the Valsartan 160 mg and the Indapamide SR 1.5 mg for 2 months. The use of drugs was prescribed for 2 months. 24-hour blood pressure monitoring was carried out in all patients using the device ABPM 04 (Hungary) according to conventional method. Renal function was assessed by creatinine clearance (Cockcroft-Gault) and glomerular filtration rate (MDRD). Both соmbinations of the drugs have sufficient antihypertensive effect – in the group of patients treated with the Noliprel A avg. SBP decreased from 164,45±3,1 to 136,0±2,2 mm Hg (p<0,01), avg. DBP – from 99,2±2,4 to 81,4±2,1 mm Hg (p<0,01); in the Valsartan group – from 161,05±2,30 to 145.90±2,07 mmHg (p<0,01) and from 101,35 ± 1,49 to 87,50±1.07mm Hg (p<0.01), respectively. Patients with adverse circadian blood pressure profiles predominated (30 (78.9%), these patients were classified as non-dipper, 8 (21.1%) – as dipper). After 2 months of therapy with the Noliprel, the number of dipper increased to 13 (68.4%) patients; in the group treated with the Valsartan and the Indapamide – to 8 (42.1%). The results of the Noliprel A Forte therapy allowed to reveal a statistically significant improvement of the functional state of the kidneys: creatinine clearance calculated according to the formula of Cockroft-Gault increased by 7.2±0,36 ml/min, GFR (MDRD formula) increased by 6.1±ml/min/1.73 m2. The Noliprel A Forte and combined therapy with the Valsartana and the Indapamide have similar antihypertensive effect. However, in patients of the group of the Noliprel A Forte often normalization circadian profile HELL was noted. The Noliprel A Forte has a significant positive influence on the functional state of the kidneys.

40 patients with diabetes mellitus type 2 (avg. age 63.2±1.2) with diabetic nephropathy and hypertension were examined. The patients were randomized into 2 groups (20 patients in each group). The patients of the first group were treated a fixed combination of 2 drags: the Perindopril 5 mg and the Indapamide 1,25 mg (Noliprel A Forte). The patients of the second group were treated a free combination of the Valsartan 160 mg and the Indapamide SR 1,5 mg for 2 months. 24-hours arterial pressure monitoring was conducted in patients twice using the device AVRM - 04 (Hungary) according to the conventional method. Saltsensitivity of BP was evaluated by the method (Weinberger MN, 1986). After 2 months of therapy, avg. SBP in the patients of the first group decreased from 152,75±1,5 to 128,4±0,9 mmHg (pO.01), avg. DBP - from 88.95±1.9 to 75.45±0.7 mmHg (p<0,05); in the patients of group 2 from 153,2±1,3 mmHg to 133,7±0,9 (p<0.05) and from 89,15±1,9 to 77,85±0,9 mmHg (p<0,05), respectively. Both combinations of drags were most effective in the patients with saltsensitivity of hypertension: administration of the Noliprel in saltsensitive patients resulted in absolute reduction of avg. SAD by 27,8±0,7 mm Hg vs 18,3±0,4 mm Hg in saltresistant ones, p<0,01, avg. DAD decreased by 13,7±1,5 mm Hg vs 9,0±1,08 mm Hg, p<0,05, respectively; administration of the Valsartan and the Indapamide in saltsensitive patients resulted in avg. SAD decrease by 18,4±0,7 mm Hg vs 12,2±0,5 mm Hg in saltresistant ones, p <0.01, avg. DAD - by 10,3±1,2 mm Hg vs 6,7±0,9 mm Hg p<0,05, respectively. Both combinations of drags showed a comparable antihypertensive effect, which was significantly more pronounced in the saltsensitive patients.

No abstract